United States Neurofibromatosis Type 2 Market Set to Surge with Innovative Therapies and Growing Patient Awareness 2025 | Top key players - AstraZeneca Plc, Vivace Therapeutics, Ikena Oncology, Inc.

Market Overview:

The Global Neurofibromatosis Type 2 Market is expected to reach at a Significant CAGR during the forecast period 2024-2031.

The Neurofibromatosis Type 2 Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/neurofibromatosis-type-2-market?sz

The Neurofibromatosis Type 2 (NF2) Market encompasses the development, commercialization, and adoption of therapies, diagnostics, and medical interventions for NF2-a rare genetic disorder characterized by the growth of benign tumors in the nervous system, particularly vestibular schwannomas. The market includes pharmaceuticals, gene therapies, surgical devices, and diagnostic tools aimed at improving patient outcomes and managing tumor progression.

Recent Key Developments of United States (U.S):

Late-Stage NF2 Clinical Trials: Two U.S.-supported NF2 clinical trials for progressive Vestibular Schwannomas (Aspirin and Crizotinib) were listed as actively recruiting patients as of September 17, 2025.

Major NF Conference: The 2025 NF Conference (June 21-24, 2025, in Washington, D.C.) focused on "cutting-edge advances in AI, drug repositioning, and precision medicine" for the NF community, including NF2-related schwannomatosis.

NF2 Gene Therapy Focus: A dedicated US-based company, NF2 Therapeutics, Inc., is actively developing an AAV-based gene therapy for vestibular schwannomas in NF2 and an antibody-drug conjugate targeting meningiomas, with support from the Children's Tumor Foundation.

Recruiting NF2 Drug Trial: A clinical trial examining the efficacy of mirdametinib (a MEK inhibitor, already FDA-approved for NF1-PN) in adult NF1 patients was recruiting at Johns Hopkins, though the NF2 clinical trials listed there were already established.

Multidisciplinary Clinic Focus: Major US medical centers, such as UT Southwestern and Washington University, continued to highlight their multidisciplinary NF2 programs offering advanced treatments like bevacizumab and Auditory Brainstem Implants (ABI), emphasizing comprehensive care is the current standard in 2025.

List of the Key Players in the Neurofibromatosis Type 2 Market:

Manus Aktteva Biopharma LLP
AstraZeneca Plc
OCEAN PHARMACEUTICAL
Vivace Therapeutics
Ikena Oncology, Inc.
Recursion Pharmaceuticals Inc.

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=neurofibromatosis-type-2-market

Segments Covered in the Neurofibromatosis Type 2 Market:

By Tumor Type: Vestibular Schwannomas, Meningiomas, Other Tumors.

By Treatment Type: Surgery (Tumor Removal, Stereotactic Radiosurgery, Others), Radiation Therapy), Drug Therapy (Lapatinib, Selumetinib, Bevacizumab, Others), Others.

By End-User: Hospitals, Cancer Centers, Others.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/neurofibromatosis-type-2-market?sz

Chapter Outline

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Neurofibromatosis Type 2 market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Neurofibromatosis Type 2 Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The Global Neurofibromatosis Type 2 market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Neurofibromatosis Type 2 Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Neurofibromatosis Type 2 Market in 2025?
◆ What is the projected growth rate of the Neurofibromatosis Type 2 Market through 2033?
◆ Who are the key players in the Neurofibromatosis Type 2 Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.